Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Randomized Double-blind Placebo-controlled Single and Multiple Ascending Dose Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis

Trial Profile

A Phase 1a/1b Randomized Double-blind Placebo-controlled Single and Multiple Ascending Dose Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs EDP 1066 (Primary)
  • Indications Atopic dermatitis; Psoriasis
  • Focus Adverse reactions; Biomarker; First in man
  • Sponsors Evelo Biosciences
  • Most Recent Events

    • 14 Feb 2019 According to an Evelo Biosciences media release, initial data anticipated in the second quarter of 2019.
    • 14 Feb 2019 According to an Evelo Biosciences, Following completion of each of the three dose-ascending healthy volunteer cohorts, data was reviewed by the trials safety review committee and the trial proceeded as planned into cohorts of patients with atopic dermatitis or psoriasis.
    • 31 May 2018 According to an Evelo Biosciences media release, the first subject was dosed in this trial in April 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top